ALZN Alzamend Neuro
- 0.7300
- +0.0190+2.67%
Alzamend Neuro News
Alzamend Neuro | 8-K: Current report
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-Director AULT MILTON C III
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-Director AULT MILTON C III
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-Director AULT MILTON C III
Alzamend Neuro | 8-K: Current report
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-Director AULT MILTON C III
Alzamend Neuro | 10-Q: Quarterly report
Alzamend Neuro | DEF 14A: Definitive information statements
Alzamend Neuro | 8-K: Current report
Alzamend Neuro | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Alzamend Neuro | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Alzamend Neuro | 8-K: Current report
Alzamend Neuro | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-MILTON C. AULT, III(40.3%),AULT ALLIANCE, INC.(25.4%), etc.
Alzamend Neuro | 8-K: Current report
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-Director AULT MILTON C III
Alzamend Neuro | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-MILTON C. AULT, III(29.4%),AULT LIFE SCIENCES, INC.(15.1%), etc.
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-Director AULT MILTON C III
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-Director AULT MILTON C III
Alzamend Neuro | 8-K: Current report
Alzamend Neuro | 4: Statement of changes in beneficial ownership of securities-10% Owner AULT MILTON C III
Analysis
Price Target
No Data
